Skip to content
PharmaceuticalsBad Homburg, HessenDAX 40 No programme known Updated on 07/10/2026

Job cuts at Fresenius SE & Co.: severance pay and your rights

What employees need to know now: status of the cuts, severance practice and your rights.

Updated on 07/10/2026

Employees in GermanyEmployees DE

86,606

As of 2025

RevenueRevenue

€22.6 billion

Group, financial year

HeadquartersHeadquarters

Bad Homburg

Hesse

Stock exchange listingStock exchange

DAX 40

Industry Pharmaceuticals

Severance factorSeverance factor

0.6 to 1.1

Monthly salaries per year

The factor range is our estimate, not a commitment by the company. The actual severance pay depends on the individual case, in particular length of service, age and pay grade.

Severance pay at Fresenius SE & Co.

Severance factor

0.6 to 1.1

Monthly salaries per year of employment

Editorial estimate
  1. 0
  2. 0,5
  3. 1,0
  4. 1,5
  5. 2,0

Vertical line: rule of thumb 0.5, no legal entitlement

Base amount

not known

Negotiating partner

Works council, ver.di and Marburger Bund

Current arrangements

Fresenius has not published a job reduction programme with a specific number of positions. Under CEO Michael Sen, a far-reaching group restructuring has been under way since 2022, together with a savings programme that most recently delivered productivity gains of just under half a billion euros. On possible job cuts at its hospital subsidiary Helios, the company is reserved and points to its dialogue with works councils (Betriebsrat). Pressure is growing because of the savings measures planned by the statutory health insurers, which hit Helios, as the largest private hospital operator, directly. The recent fall in headcount was mainly due to portfolio effects, not job cuts.

Assessment of the severance factor

Only the reduction at the pharmaceutical subsidiary Kabi has recently been quantified: according to a report in the Handelsblatt, Fresenius plans to cut 2,000 jobs there, 250 of them in Germany; the company did not confirm this and pointed to the cost and efficiency programme still being worked out. Because there is otherwise no quantified programme and no overarching social plan (Sozialplan), we derive a factor of 0.8, with a range of 0.6 to 1.1. In favour of this are the strong position of ver.di and Marburger Bund in the healthcare sector, the collective bargaining coverage of many Helios companies and the group's good earnings position, with a raised annual forecast. On the other hand, separations without a collective framework are negotiated individually, and pay levels differ widely depending on the role.

The factor is our assessment, not a commitment from the company. At Fresenius, what matters most is which company your contract is with and which collective agreement applies there; medical staff negotiate on different standards from nursing or service staff. Length of service, age and any special protection against dismissal also play a role. Further circumstances of the individual case come into play as well.

The factor is our estimate, derived from industry, region, co-determination and economic situation, and is not a commitment by the company. Length of service, age and special protection against dismissal can shift the result considerably.

Severance calculator

What you could be entitled to at Fresenius SE & Co.

€
years

Possible severance pay

–

Special protection against dismissal?

€
Have your offer checked for free

Non-binding guidance based on the standard formula, not legal advice. There is only a right to severance pay in exceptional cases; the actual amount depends on the individual case, for example on age, maintenance obligations and whether the dismissal is valid. AbfindungsHero puts you in touch with employment law firms and does not provide legal services itself.

Headcount development

Fresenius SE & Co. KGaA, Germany

Source: annual reports

  1. 90,655 21
  2. 91,093 22
  3. 93,095 23
  4. 86,101 24
  5. 86,606 25

2024 · Deconsolidation of Fresenius Medical Care in November 2023 and disposal of the Vamed hospital project business. The decline compared with 2023 is a portfolio effect, not a job cut. No figures defined on this basis are available for the years before 2021. Scale starts at 75,000, not at zero.

Timeline of the job cuts

  1. 2025 Ongoing Savings programme at the hospital subsidiary Helios For its hospital division Helios, Fresenius announced a savings programme that is expected to improve the result of the German hospitals by around 100 million euros from 2025. This includes shorter lengths of stay, better management of patient flows, centralisation of hospitals by specialty and savings in purchasing. Areas not directly involved in patient care, such as IT, are to be modernised and centralised; according to CEO Michael Sen, this may also involve staffing adjustments, but no figures were given.
  2. 2024 Ongoing 2,000 jobs Cost and efficiency programme at the subsidiary Fresenius Kabi According to a report in the Handelsblatt, Fresenius plans to cut 2,000 jobs in its pharmaceutical division Kabi, 250 of them in Germany. The company did not confirm the figures and pointed out that the specific measures under the already announced cost and efficiency programme were still being worked out. Fresenius Kabi employs more than 40,000 people worldwide.

Fresenius SE & Co. KGaA: job cuts, severance pay and employees' rights

No quantified reduction programme, but growing pressure

Fresenius has not announced a job reduction programme with a specific number of positions. Under CEO Michael Sen, who has been in office since October 2022, a far-reaching group restructuring is under way, with a savings programme that most recently delivered productivity gains of just under half a billion euros. Asked about job cuts at its hospital subsidiary Helios, the company deliberately answers with caution: it will enter into dialogue with social partners and works councils (Betriebsrat) as soon as it is clear how the concepts affect staffing needs.

Why this could change

The pressure comes from outside. In the first quarter of 2026, spending by the statutory health insurers rose by 7.6 per cent, while contribution income rose by only 4.1 per cent. A funding gap of 19 billion euros is cited for the coming year. The insurers' planned savings measures hit private hospital operators directly, and with more than 80 hospitals in Germany, Helios is the largest. If the hospital reform arrives at the same time, investment and restructuring plans come under additional pressure.

What the figures show and what they do not

The group's headcount fell from around 194,000 in 2023 to around 179,000 in 2024. This decline is not a job cut but the result of portfolio decisions: the dialysis subsidiary Fresenius Medical Care was deconsolidated in November 2023, and the Vamed hospital project business was disposed of in 2024. The figures before and after these steps are not comparable.

At Fresenius, outsourcing individual areas to service companies is a more common occurrence than dismissal. If an area such as catering, cleaning or logistics is transferred to another company, the employment relationship transfers with all rights and obligations, length of service continues to count, and a dismissal solely because of the transfer would be invalid. What matters is what changes afterwards: collective bargaining coverage, pay grading and the responsible works council may be different in the new company. Have such a change to your contract reviewed before you agree to it.

At Fresenius, negotiations are held with the works council and ver.di, and in the medical service also with Marburger Bund.

How the group is doing

Fresenius is growing again: in 2025 revenue rose to just under 22.6 billion euros, adjusted EBIT rose by a good four per cent to 2.6 billion euros, and the dividend rises to 1.05 euros per share. In the second quarter of 2026, revenue grew by five per cent to 5.86 billion euros and EBIT by ten per cent at constant currency to 719 million euros; the annual forecast was raised. Helios operates more than 80 hospitals in Germany alone and recently benefited from positive effects of its own savings programme. On 1 July 2026, Christian Pawlu took over as head of the hospital division.

What this means for employees

A profitable group that keeps saving rarely cuts staff with a big announcement. It does so through unfilled vacancies, restructuring of individual hospitals and the outsourcing of service areas. Anyone working in hospital operations should therefore watch two things in particular: whether their own company is bound by a collective agreement, and whether areas such as catering, cleaning or logistics are being moved into separate service companies. Both change your negotiating position more than any group announcement.

Where figures have already been given

So far, specifics have emerged only in the pharmaceutical division: according to a report in the Handelsblatt, Fresenius plans to cut 2,000 jobs at Kabi, 250 of them in Germany. The company did not confirm the figures and pointed out that the measures under the cost and efficiency programme were still being worked out. For the hospital division, CEO Michael Sen announced that areas not directly involved in patient care, such as IT, would be modernised and centralised; this could also involve staffing adjustments, although he gave no figures. At the same time, worldwide headcount fell to around 180,000 by the end of 2024, mainly because of disposals such as Vamed and the fertility clinic chain Eugin.

In healthcare, a lot depends on the applicable collective agreement and on who exactly your employer is: the hospital itself, a service company or a subsidiary. An employment lawyer from our network will clarify this with you in a free initial consultation and tell you what an offer is worth.

Affected by job cuts at Fresenius SE & Co.?

Whether an offer is fair can only be judged on the specific case. An employment law firm will assess your situation free of charge.